The FDA on June 17, 2019 granted accelerated approval to KEYTRUDA® for patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. KEYTRUDA® is a product of Merck.
Other Pages – Bottom Ad
Advertisement
Subscribe
